{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T20:06:07Z","timestamp":1699301167092},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T00:00:00Z","timestamp":1578700800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T00:00:00Z","timestamp":1578700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40261-019-00883-5","type":"journal-article","created":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T14:02:50Z","timestamp":1578751370000},"page":"259-268","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Pharmacokinetics, Safety and Exploratory Efficacy Study of a Topical Bactericidal VB-1953: Analysis of Single and Multiple Doses in a Phase I Trial in Acne Vulgaris Subjects"],"prefix":"10.1007","volume":"40","author":[{"given":"Shilpi","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,11]]},"reference":[{"issue":"8","key":"883_CR1","first-page":"734","volume":"86","author":"S Titus","year":"2012","unstructured":"Titus S, Hodge J. Diagnosis and treatment of acne. Am Fam Physician. 2012;86(8):734\u201340.","journal-title":"Am Fam Physician"},{"issue":"Suppl 1","key":"883_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjd.13462","volume":"172","author":"JK Tan","year":"2015","unstructured":"Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3\u201312.","journal-title":"Br J Dermatol"},{"issue":"5","key":"883_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1365-2230.1981.tb02336.x","volume":"6","author":"WJ Cunliffe","year":"1981","unstructured":"Cunliffe WJ, Clayden AD, Gould D, Simpson NB. Acne vulgaris\u2014its aetiology and treatment. A review. Clin Exp Dermatol. 1981;6(5):461\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl 1","key":"883_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04374.x","volume":"26","author":"A Nast","year":"2012","unstructured":"Nast A, Dreno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, et al. European evidence based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl 1):1\u201329.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 Suppl","key":"883_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaad.2009.01.019","volume":"60","author":"D Thiboutot","year":"2009","unstructured":"Thiboutot D, Gollnick H, Bettoli V, Dr\u00e9no B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(5 Suppl):S1\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"883_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1517\/14728214.2015.990373","volume":"20","author":"I Aslam","year":"2015","unstructured":"Aslam I, Fleischer A, Feldman S. Emerging drugs for the treatment of acne. Expert Opin Emerg Drugs. 2015;20(1):91\u2013101.","journal-title":"Expert Opin Emerg Drugs."},{"issue":"1","key":"883_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0190-9622(83)70005-8","volume":"8","author":"JJ Leyden","year":"1983","unstructured":"Leyden JJ, McGinley KJ, Cavalieri S, Webster GF, Mills OH, Kligman AM. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol. 1983;8(1):41\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"883_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2133.2005.06614.x","volume":"153","author":"T Simonart","year":"2005","unstructured":"Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol. 2005;153(2):395\u2013403.","journal-title":"Br J Dermatol"},{"key":"883_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3201\/eid0702.010239","volume":"7","author":"DC Hooper","year":"2001","unstructured":"Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001;7:337\u201341.","journal-title":"Emerg Infect Dis"},{"issue":"35","key":"883_CR10","doi-asserted-by":"publisher","first-page":"22615","DOI":"10.1074\/jbc.273.35.22615","volume":"273","author":"SC Kampranis","year":"1998","unstructured":"Kampranis SC, Maxwell A. The DNA gyrase-quinolone complex. ATP hydrolysis and the mechanism of DNA cleavage. J Biol Chem. 1998;273(35):22615\u201326.","journal-title":"J Biol Chem"},{"issue":"4","key":"883_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/0190-9622(91)70252-W","volume":"25","author":"I Kurokawa","year":"1991","unstructured":"Kurokawa I, Akamatsu H, Nishijima S, Asada Y, Kawabata S. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J Am Acad Dermatol. 1991;25(4):674\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"883_CR12","first-page":"44","volume":"9","author":"H Sch\u00f6fer","year":"2009","unstructured":"Sch\u00f6fer H, G\u00f6llner A, Kusche W, Schwantes U. Effectiveness and tolerance of topical nadifloxacin in the therapy of acne vulgaris (grade I-II): results of a non-interventional trial in 555 patients. J Appl Res. 2009;9(3):44\u201351.","journal-title":"J Appl Res."},{"issue":"1","key":"883_CR13","first-page":"48","volume":"16","author":"G Plewig","year":"2006","unstructured":"Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol. 2006;16(1):48\u201355.","journal-title":"Eur J Dermatol."},{"issue":"2","key":"883_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.12788\/j.sder.2016.031","volume":"35","author":"M Sinha","year":"2016","unstructured":"Sinha M, Sadhasivam S, Bhattacharyya A, Jain S, Ghosh S, Arndt KA, et al. Antibiotic-resistant acne: getting under the skin. Semin Cutan Med Surg. 2016;35(2):62\u20137.","journal-title":"Semin Cutan Med Surg"},{"issue":"2","key":"883_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/00128071-200405020-00002","volume":"5","author":"HH Tan","year":"2004","unstructured":"Tan HH. Topical antibacterial treatments for acne vulgaris: comparative review and guide to selection. Am J Clin Dermatol. 2004;5(2):79\u201384.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"883_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/dth.12391","volume":"29","author":"S Sadhasivam","year":"2016","unstructured":"Sadhasivam S, Sinha M, Saini S, Kaur SP, Gupta T, Sengupta S, et al. Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes. Dermatol Ther. 2016;29(6):451\u20134.","journal-title":"Dermatol Ther"},{"issue":"6","key":"883_CR17","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.jid.2017.11.041","volume":"138","author":"S Ghosh","year":"2018","unstructured":"Ghosh S, Sinha M, Bhattacharyya A, Sadhasivam S, Megha J, Reddy S, et al. A rationally designed multifunctional antibiotic for the treatment of drug-resistant acne. J Invest Dermatol. 2018;138(6):1400\u20138.","journal-title":"J Invest Dermatol."},{"issue":"5","key":"883_CR18","doi-asserted-by":"publisher","first-page":"S104","DOI":"10.1016\/j.jid.2019.03.684","volume":"139","author":"R Batra","year":"2019","unstructured":"Batra R, Sadhasivam S, Saini S, Gupta S, Jain S, Secci A, et al. A clinical study to test the efficacy of VB-1953 in clindamycin non-responder acne patients with antibiotic-resistant P. acnes. J Invest Dermatol. 2019;139(5):S104. https:\/\/doi.org\/10.1016\/j.jid.2019.03.684.","journal-title":"J Invest Dermatol."},{"key":"883_CR19","unstructured":"Guidance for industry: Acne vulgaris: developing drugs for treatment, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2005."},{"issue":"3","key":"883_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1365-4632.2010.04701.x","volume":"50","author":"JY Jung","year":"2011","unstructured":"Jung JY, Kwon HH, Yeom KB, Yoon MY, Suh DH. Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol. 2011;50(3):350\u20137.","journal-title":"Int J Dermatol"},{"issue":"7","key":"883_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2165\/00128071-200304070-00004","volume":"4","author":"A Akhavan","year":"2003","unstructured":"Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure and safety. Am J Clin Dermatol. 2003;4(7):473\u201392.","journal-title":"Am J Clin Dermatol"},{"key":"883_CR22","unstructured":"ACZONE\u00ae (dapsone) Gel, 7.5%, for topical use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207154s003lbl.pdf. Accessed 05 July 2019."},{"key":"883_CR23","unstructured":"DIFFERIN\u00ae (adapalene) Gel, 0.3%. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021753lbl.pdf. Accessed 05 July 2019."},{"key":"883_CR24","unstructured":"BenzaClin\u00ae topical Gel (clindamycin - benzoyl peroxide gel). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050756s037lbl.pdf. Accessed 05 July 2019."},{"key":"883_CR25","unstructured":"Ziana\u2122 (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/050802lbl.pdf. Accessed 05 July 2019."},{"issue":"Suppl 1","key":"883_CR26","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1111\/j.1468-3083.1998.tb00902.x","volume":"11","author":"EJ van Hoogdalem","year":"1998","unstructured":"van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol. 1998;11(Suppl 1):S13\u20139 (discussion S28-9).","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00883-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00883-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00883-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T01:16:26Z","timestamp":1610241386000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00883-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,11]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["883"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00883-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,11]]},"assertion":[{"value":"11 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Vyome Therapeutics Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SJ and VY are employees of Vyome Therapeutics Ltd. NB is a consultant to Vyome Therapeutics Limited and has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the principles of Good Clinical Practice (GCP) and with the 1964 Helsinki Declaration and its later amendments. The central Institutional Review Board (IRB), Quorum Review IRB, Seattle, USA approval was sought at the site for the initial protocol and for protocol amendments. Written informed consent was obtained from all individual participants included in the study before commencing any study-related procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}